Nian Wu, Ph.D.
Chief Executive Officer

Founder and lead inventor of the Liposeuticals technology platform, Dr. Nian Wu has over 30 years of experience in pharmaceutical product R&D, product formulation and project management. He was formerly a Research Faculty and Group Head from 2004 to 2013 at Memorial Sloan-Kettering Cancer Center (MSKCC) and adjunct professor at Gerstner Sloan-Kettering Graduate School of Biomedical Sciences in New York City, and prior to that worked at Schering-Plough (now Merck & Co.), Wyeth-Ayerst (now Pfizer), and Alpharma (also now part of Pfizer). He has published over 60 research articles and is listed as an inventor or co-inventor on over 20 patents. He earned a master degree in chemistry from the University of Scranton in Scranton, PA, obtained his Ph.D. in chemistry from the State University of New York and did his postdoctoral work in the University of Illinois at Urbana-Champaign.

Lacarya Scott, M.S., M.B.A.
Executive Vice President

As the senior executive of LipoSeuticals, Mr. Scott has 7 years of experience in M&A and licensing within two large public biotechnology companies, and 10 years buyside public and private experience investing and serving on the boards of biotech and pharma companies. He has a strong science background to complement his financial and business skillset. Mr. Scott is a financial and corporate strategy advisor in biotech industry. He earned his A.D. in molecular biology from Princeton University, MS in Biology from New York University, M.S. Engineering Biotechnology and MBA from the University of Pennsylvania.

Lan-Bo Chen, Ph.D.
Board Director and Scientific Advisor

Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He received his Ph.D. in cell biology from the Massachusetts Institute of Technology and elected as an academician of the Academia Sinica of Taiwan. He is the author of over 250 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Madrigal/Synta Pharmaceuticals and Sequential Medicine. Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates.

Joseph Vinson, Ph.D.
Board Director and Scientific Advisor

Dr. Vinson is Professor Emeritus of Chemistry at University of Scranton. He received his Ph.D. in Chemistry from the Iowa State University. His research has been featured in Prevention, Psychology Today, Consumer Reports, AARP, Tufts Health & Nutrition Newsletter, US News & World Report and lam pooned in a cartoon in Time magazine. He has appeared on TV-Good Morning America Sunday and radio-NPR “All Things Considered” and “The Peoples Pharmacy,” as well as being mentioned by Jay Leno and Rush Limbaugh. Dr. Vinson is the author of over 70 publications. His research interests are wide-ranging and include drug analysis in physiological fluids and the effect of vitamins, minerals, and antioxidants on nutrition and health.